مقال بحثي وصول مفتوح
Managing the Adverse Events Associated with Pembrolizumab and Lenvatinib Therapy in Endometrial Cancer
Endometrial cancer (EC) is the most common gynaecological cancer. The combination of lenvatinib and pembrolizumab has exhibited efficacy as the second line treatment for advanced EC, with a significant benefit in terms of progression free survival (PFS) and overall survival, but the adverse events (AE) profile is compl …